Lupin Acquires VISUfarma from GHO Capital

Grundium Acquires Visiopharm

May 25, 2026

AI & Machine Learning

Grundium announced it has acquired Visiopharm to create an integrated precision pathology platform that combines digital slide scanning with AI-driven pathology software. The combined offering is intended to support diagnostic laboratories, biopharmaceutical development, and research organizations with more scalable, cost-effective digital pathology workflows, including biomarker assessment and clinical research use cases.

Faes Farma to Acquire SIFI to Build Leading Ophthalmology Franchise

June 10, 2025

Healthcare Services

SIFI shareholders have signed an agreement to sell 100% of SIFI shares to Faes Farma, a European pharmaceutical company listed on the Spanish stock exchange. The deal is expected to close in Q3 2025, subject to regulatory approvals and Faes Farma’s extraordinary shareholders’ meeting.

Lupin Healthcare Acquires Renascience Pharma Limited (UK)

April 2, 2025

Pharmaceuticals

Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Limited, has acquired UK-based Renascience Pharma Limited, the sole supplier of four specialty branded products in the UK. The acquisition (reported at approximately £12.3 million) expands Lupin's branded specialty portfolio in the UK and strengthens its supply offerings to the NHS across infectious disease, ENT and cardiology/renal indications.

Tenpoint Therapeutics and Visus Therapeutics Complete Merger to Advance Ophthalmic Pipeline

December 12, 2024

Biotechnology

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. completed a merger to combine their ophthalmic drug development programs, bringing the late-stage presbyopia candidate BRIMOCHOL PF together with Tenpoint’s broader aging-eye pipeline. The combined company is launching a crossover financing round with participation from institutional investors to support an NDA filing and a planned US commercial launch of BRIMOCHOL PF in the 1H of 2026. Henric Bjarke was named CEO of the merged company.

Visiox Pharmaceuticals Announces Definitive Merger With Ocuvex Therapeutics

August 19, 2024

Healthcare Services

Visiox Pharmaceuticals, Inc. entered into a definitive merger agreement with Ocuvex Therapeutics, Inc., an ophthalmic pharmaceutical company focused on developing and commercializing therapies for glaucoma and other eye disorders. The combined company will operate under the Ocuvex name, aiming to strengthen its ophthalmic portfolio and accelerate commercialization of near-term products.

Nordic Pharma (via Amring) Acquires Visant Medical to Launch LACRIFILL in U.S.

December 18, 2023

Medical Devices

Nordic Pharma Group B.V., through its U.S. subsidiary Amring Pharmaceuticals Inc., has completed the acquisition of Visant Medical, Inc., bringing the FDA-cleared hyaluronic acid canalicular occlusive device LACRIFILL into the Nordic Pharma portfolio. Nordic will launch and commercialize LACRIFILL in the United States, expanding its ophthalmology product offering and enabling future global regulatory filings.